Literature DB >> 641391

Hemoperfusion removal of digoxin from dogs.

T P Gibson, S V Lucas, H A Nelson, A J Atkinson, G T Okita, P Ivanovich.   

Abstract

Removal of digoxin by XAD-4 hemoperfusion columns was tested after four dogs were given 0.06 mg/kg of digoxin i.v. Dogs were perfused for 4 to 5 hr at a flow of 105 ml/min through a 100 gm XAD-4 column 16 hr after the dose. Pharmacokinetic analysis of digoxin levels was performed with a three-compartment model. The apparent postdistribution t1/2 was 16.0 +/- 2.9 (S.D.) hr and decreased to 7.1 +/- 2.1 hr during perfusion. Digoxin perfusion clearance was 46 ml/min. An average of 51 microgram of digoxin was recovered from used columns. CP of digoxin calculated from the total R was 127.5 +/- 13 ml/min or 2.3 times greater than plasma flow. With the use of 3H-digoxin, canine blood was found to contain 2.5 times as much digoxin as did plasma. After perfusion there was an increase in serum digoxin levels in all dogs. Computer analysis showed that the increase in plasma digoxin levels immediately after hemoperfusion occurred because the central compartment, which was depleted of digoxin during hemoperfusion, was refilled from peripheral compartments. This study demonstrated that (1) XAD-4 hemoperfusion doubles the rate of removal of digoxin from dogs, (2) dog whole blood contains more than twice as much digoxin than does plasma, so that hemoperfusion clearance exceeds plasma flow, and (3) a multicompartmental pharmacokinetic model explains the increase in serum digoxin concentrations observed at the completion of hemoperfusion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 641391

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  2 in total

1.  Specific hemoperfusion through agarose acrobeads.

Authors:  S Margel; L Marcus
Journal:  Appl Biochem Biotechnol       Date:  1986-02       Impact factor: 2.926

2.  Haemoperfusion in the management of digoxin toxicity: is it warranted?

Authors:  J T Slattery; J R Koup
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.